annual CFF:
$17.36M+$200.39M(+109.49%)Summary
- As of today (July 1, 2025), PCRX annual cash flow from financing activities is $17.36 million, with the most recent change of +$200.39 million (+109.49%) on December 31, 2024.
- During the last 3 years, PCRX annual CFF has fallen by -$363.33 million (-95.44%).
- PCRX annual CFF is now -95.44% below its all-time high of $380.69 million, reached on December 31, 2021.
Performance
PCRX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$2.99M-$1.04M(-53.15%)Summary
- As of today (July 1, 2025), PCRX quarterly cash flow from financing activities is -$2.99 million, with the most recent change of -$1.04 million (-53.15%) on March 31, 2025.
- Over the past year, PCRX quarterly CFF has dropped by -$177.00 thousand (-6.28%).
- PCRX quarterly CFF is now -100.83% below its all-time high of $361.41 million, reached on December 31, 2021.
Performance
PCRX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$17.19M-$177.00K(-1.02%)Summary
- As of today (July 1, 2025), PCRX TTM cash flow from financing activities is $17.19 million, with the most recent change of -$177.00 thousand (-1.02%) on March 31, 2025.
- Over the past year, PCRX TTM CFF has increased by +$49.13 million (+153.80%).
- PCRX TTM CFF is now -95.49% below its all-time high of $380.69 million, reached on December 31, 2021.
Performance
PCRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PCRX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +109.5% | -6.3% | +153.8% |
| 3 y3 years | -95.4% | +98.3% | -90.9% |
| 5 y5 years | +373.1% | -133.7% | +983.6% |
PCRX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -95.4% | +104.3% | -112.0% | +98.0% | -41.2% | +104.3% |
| 5 y | 5-year | -95.4% | +104.3% | -100.8% | +98.3% | -95.5% | +104.3% |
| alltime | all time | -95.4% | +104.3% | -100.8% | +98.3% | -95.5% | +104.3% |
PCRX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$2.99M(+53.1%) | $17.19M(-1.0%) |
| Dec 2024 | $17.36M(-109.5%) | -$1.96M(-31.3%) | $17.36M(-1.0%) |
| Sep 2024 | - | -$2.85M(-111.4%) | $17.54M(-336.9%) |
| Jun 2024 | - | $24.98M(-986.8%) | -$7.40M(-76.8%) |
| Mar 2024 | - | -$2.82M(+58.3%) | -$31.94M(-82.5%) |
| Dec 2023 | -$183.03M(-54.4%) | -$1.78M(-93.6%) | -$183.03M(-23.7%) |
| Sep 2023 | - | -$27.79M(-6415.2%) | -$239.76M(+9.1%) |
| Jun 2023 | - | $440.00K(-100.3%) | -$219.75M(-41.2%) |
| Mar 2023 | - | -$153.91M(+163.0%) | -$373.85M(-6.9%) |
| Dec 2022 | -$401.53M(-205.5%) | -$58.51M(+652.6%) | -$401.53M(-2283.2%) |
| Sep 2022 | - | -$7.78M(-94.9%) | $18.39M(-37.1%) |
| Jun 2022 | - | -$153.66M(-15.4%) | $29.22M(-84.5%) |
| Mar 2022 | - | -$181.59M(-150.2%) | $188.78M(-50.4%) |
| Dec 2021 | $380.69M(+71.2%) | $361.41M(>+9900.0%) | $380.69M(+1184.0%) |
| Sep 2021 | - | $3.05M(-48.3%) | $29.65M(-87.5%) |
| Jun 2021 | - | $5.91M(-42.8%) | $236.35M(+1.0%) |
| Mar 2021 | - | $10.32M(-0.4%) | $233.91M(+5.2%) |
| Dec 2020 | $222.30M(+5957.3%) | $10.36M(-95.1%) | $222.30M(+5.9%) |
| Sep 2020 | - | $209.76M(+5955.4%) | $209.92M(>+9900.0%) |
| Jun 2020 | - | $3.46M(-370.4%) | $1.59M(-14.7%) |
| Mar 2020 | - | -$1.28M(-36.6%) | $1.86M(-49.3%) |
| Dec 2019 | $3.67M(-59.0%) | -$2.02M(-242.0%) | $3.67M(-60.2%) |
| Sep 2019 | - | $1.42M(-61.9%) | $9.22M(-14.5%) |
| Jun 2019 | - | $3.74M(+605.1%) | $10.78M(+18.9%) |
| Mar 2019 | - | $530.00K(-85.0%) | $9.06M(+1.2%) |
| Dec 2018 | $8.95M(-96.0%) | $3.53M(+18.3%) | $8.95M(+16.2%) |
| Sep 2018 | - | $2.98M(+47.3%) | $7.71M(+4.0%) |
| Jun 2018 | - | $2.02M(+383.3%) | $7.41M(-4.1%) |
| Mar 2018 | - | $419.00K(-81.6%) | $7.72M(-96.6%) |
| Dec 2017 | $224.16M | $2.28M(-15.2%) | $224.16M(+0.5%) |
| Sep 2017 | - | $2.69M(+15.0%) | $222.95M(+0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $2.34M(-98.9%) | $221.03M(-0.0%) |
| Mar 2017 | - | $216.86M(>+9900.0%) | $221.08M(+2944.7%) |
| Dec 2016 | $7.26M(-32.1%) | $1.07M(+39.1%) | $7.26M(-13.2%) |
| Sep 2016 | - | $769.00K(-67.7%) | $8.36M(-11.2%) |
| Jun 2016 | - | $2.38M(-21.7%) | $9.42M(-2.8%) |
| Mar 2016 | - | $3.04M(+40.0%) | $9.69M(-9.4%) |
| Dec 2015 | $10.70M(-91.0%) | $2.17M(+19.1%) | $10.70M(-5.0%) |
| Sep 2015 | - | $1.82M(-31.4%) | $11.26M(-4.7%) |
| Jun 2015 | - | $2.66M(-34.3%) | $11.82M(-90.2%) |
| Mar 2015 | - | $4.05M(+47.9%) | $120.96M(+1.8%) |
| Dec 2014 | $118.88M(+33.3%) | $2.74M(+14.9%) | $118.88M(+1.6%) |
| Sep 2014 | - | $2.38M(-97.9%) | $116.95M(+1.2%) |
| Jun 2014 | - | $111.79M(+5592.2%) | $115.55M(+2237.6%) |
| Mar 2014 | - | $1.96M(+141.6%) | $4.94M(-94.5%) |
| Dec 2013 | $89.17M(+40.2%) | $813.00K(-17.0%) | $89.17M(+0.7%) |
| Sep 2013 | - | $979.00K(-17.5%) | $88.59M(+0.8%) |
| Jun 2013 | - | $1.19M(-98.6%) | $87.86M(-41.7%) |
| Mar 2013 | - | $86.19M(>+9900.0%) | $150.68M(+136.9%) |
| Dec 2012 | $63.61M(-27.0%) | $237.00K(-5.2%) | $63.61M(-43.5%) |
| Sep 2012 | - | $250.00K(-99.6%) | $112.50M(+0.2%) |
| Jun 2012 | - | $64.00M(-7373.1%) | $112.26M(+132.6%) |
| Mar 2012 | - | -$880.00K(-101.8%) | $48.26M(-44.6%) |
| Dec 2011 | $87.16M(+71.9%) | $49.13M(>+9900.0%) | $87.16M(+47.5%) |
| Sep 2011 | - | $11.00K(>+9900.0%) | $59.10M(-14.8%) |
| Jun 2011 | - | $0.00(-100.0%) | $69.40M(-14.6%) |
| Mar 2011 | - | $38.02M(+80.4%) | $81.22M(+60.2%) |
| Dec 2010 | $50.70M(+141.0%) | $21.07M(+104.4%) | $50.70M(+71.1%) |
| Sep 2010 | - | $10.31M(-12.8%) | $29.64M(+53.3%) |
| Jun 2010 | - | $11.82M(+57.6%) | $19.33M(+157.6%) |
| Mar 2010 | - | $7.50M | $7.50M |
| Dec 2009 | $21.04M(-47.6%) | - | - |
| Dec 2008 | $40.17M | - | - |
FAQ
- What is Pacira BioSciences annual cash flow from financing activities?
- What is the all time high annual CFF for Pacira BioSciences?
- What is Pacira BioSciences annual CFF year-on-year change?
- What is Pacira BioSciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Pacira BioSciences?
- What is Pacira BioSciences quarterly CFF year-on-year change?
- What is Pacira BioSciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Pacira BioSciences?
- What is Pacira BioSciences TTM CFF year-on-year change?
What is Pacira BioSciences annual cash flow from financing activities?
The current annual CFF of PCRX is $17.36M
What is the all time high annual CFF for Pacira BioSciences?
Pacira BioSciences all-time high annual cash flow from financing activities is $380.69M
What is Pacira BioSciences annual CFF year-on-year change?
Over the past year, PCRX annual cash flow from financing activities has changed by +$200.39M (+109.49%)
What is Pacira BioSciences quarterly cash flow from financing activities?
The current quarterly CFF of PCRX is -$2.99M
What is the all time high quarterly CFF for Pacira BioSciences?
Pacira BioSciences all-time high quarterly cash flow from financing activities is $361.41M
What is Pacira BioSciences quarterly CFF year-on-year change?
Over the past year, PCRX quarterly cash flow from financing activities has changed by -$177.00K (-6.28%)
What is Pacira BioSciences TTM cash flow from financing activities?
The current TTM CFF of PCRX is $17.19M
What is the all time high TTM CFF for Pacira BioSciences?
Pacira BioSciences all-time high TTM cash flow from financing activities is $380.69M
What is Pacira BioSciences TTM CFF year-on-year change?
Over the past year, PCRX TTM cash flow from financing activities has changed by +$49.13M (+153.80%)